{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:55:14Z","timestamp":1785128114101,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Rheumatoid Arthritis (RA) is a chronic autoimmune disease causing joint pain, swelling, and systemic symptoms like fatigue, with higher incidence in females and increased risk with age. It often co-exists with depression, imposing a significant global health burden with high annual cases and substantial economic losses. Sarilumab, a fully humanized IgG1 monoclonal antibody targeting the IL-6 receptor \u03b1, has shown efficacy in clinical trials but requires real-world safety monitoring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study analyzed Sarilumab-related adverse drug event (ADE) reports from the FAERS database (Q2 2017\u2013Q1 2025). Data were cleaned and analyzed using SAS 9.4, with signal detection via Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multivariate Gamma-Poisson Shrinker (MGPS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 14,940 Sarilumab users with 42,730 adverse events (AEs) were included. AE signals were detected across all 26 System Organ Classes (SOC), with the highest in Infections and Infestations (62 signals), General Disorders and Administration Site Conditions (44), Musculoskeletal and Connective Tissue Disorders (36), and Surgical and Medical Procedures (36). Nearly half of AEs occurred within 30\u202fdays (49.56%), and 15.79% after 360\u202fdays. Common AEs included pain, joint swelling, and injection site reactions, while severe reactions included serious infections and anaphylaxis. Some AEs not listed on the drug label, such as fatigue and alopecia, were also identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This real-world analysis highlights Sarilumab\u2019s safety profile, emphasizing the need for close patient monitoring, particularly during the early initiation phase and throughout long-term treatment. The findings provide valuable insights for clinicians in pre-medication assessment, during-treatment monitoring, and adverse reaction management, while underscoring the need for further research into the mechanisms and risk factors of these adverse events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1665293","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:08:01Z","timestamp":1757311681000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety of Sarilumab in the treatment of rheumatoid arthritis: a real-world study based on the FAERS database"],"prefix":"10.3389","volume":"12","author":[{"given":"Dahui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinguang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehua","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.3390\/ijms20174091","article-title":"The adipokine network in rheumatic joint diseases","volume":"20","author":"Carri\u00f3n","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/jcm12041291","article-title":"The burden of rheumatoid arthritis: findings from the 2019 global burden of diseases study and forecasts for 2030 by Bayesian age-period-cohort analysis","volume":"12","author":"Cai","year":"2023","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/add.16404","article-title":"Health and economic burden of low back pain and rheumatoid arthritis attributable to smoking in 192 countries and territories in 2019","volume":"119","author":"Chen","year":"2024","journal-title":"Addiction"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.3390\/ijms21155238","article-title":"Interleukin-6 in rheumatoid arthritis","volume":"21","author":"Pandolfi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/jcph.1795","article-title":"Differential binding of sarilumab and tocilizumab to IL-6R\u03b1 and effects of receptor occupancy on clinical parameters","volume":"61","author":"Xu","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/14740338.2024.2382227","article-title":"Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study","volume":"23","author":"Hu","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/BF03261981","article-title":"Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France","volume":"35","author":"Pariente","year":"2012","journal-title":"Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s002280000215","article-title":"Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs","volume":"56","author":"van Puijenbroek","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1002\/sim.2473","article-title":"Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events","volume":"25","author":"Nor\u00e9n","year":"2006","journal-title":"Stat Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","article-title":"A statistical methodology for drug-drug interaction surveillance","volume":"27","author":"Nor\u00e9n","year":"2008","journal-title":"Stat Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1323240","DOI":"10.3389\/fphar.2023.1323240","article-title":"Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US food and drug administration adverse event reporting system","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1186\/s12879-022-07896-0","article-title":"Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019","volume":"22","author":"Gao","year":"2022","journal-title":"BMC Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.3390\/biomedicines12122860","article-title":"IL-6R inhibitors and gastrointestinal perforations: a pharmacovigilance study and a predicting nomogram","volume":"12","author":"Zou","year":"2024","journal-title":"Biomedicine"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","article-title":"Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part a trial","volume":"73","author":"Huizinga","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/1060028018761599","article-title":"Sarilumab: review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis","volume":"52","author":"Boyce","year":"2018","journal-title":"Ann Pharmacother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-020-02163-6","article-title":"Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes","volume":"22","author":"Gabay","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s44161-023-00281-3","article-title":"Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis","volume":"2","author":"Liu","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"eabq4419","DOI":"10.1126\/scitranslmed.abq4419","article-title":"Additive efficacy of a bispecific anti-TNF\/IL-6 nanobody compound in translational models of rheumatoid arthritis","volume":"15","author":"Biesemann","year":"2023","journal-title":"Sci Transl Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"104402","DOI":"10.1016\/j.phrs.2019.104402","article-title":"IL-6 involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of IL-6 inhibitor sarilumab","volume":"149","author":"Atzeni","year":"2019","journal-title":"Pharmacol Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2014.10.023","article-title":"IL-6 regulation of synaptic function in the CNS","volume":"96","author":"Gruol","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1514080","DOI":"10.3389\/fimmu.2025.1514080","article-title":"IL-6\/IL-12 superfamily of cytokines and regulatory lymphocytes play critical roles in the etiology and suppression of CNS autoimmune diseases","volume":"16","author":"Yadav","year":"2025","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"106384","DOI":"10.1016\/j.msard.2025.106384","article-title":"Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: a six-month interim analysis of a multicenter medical chart review","volume":"98","author":"Fujihara","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"618","DOI":"10.5414\/CP204017","article-title":"Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials","volume":"59","author":"Sung","year":"2021","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1177\/1759720X17752037","article-title":"Efficacy and safety of sarilumab in patients with active rheumatoid arthritis","volume":"10","author":"McCarty","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1093\/rheumatology\/kead062","article-title":"Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis","volume":"62","author":"Burmester","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/rheumatology\/keab355","article-title":"Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors","volume":"60","author":"Fleischmann","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/mr\/roae057","article-title":"Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (<65 and \u226565\u202fyears): a post hoc analysis of Japanese phase 3 clinical trials","volume":"35","author":"Tanaka","year":"2024","journal-title":"Mod Rheumatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11010-022-04492-3","article-title":"Rheumatoid arthritis: advances in treatment strategies","volume":"478","author":"Prasad","year":"2023","journal-title":"Mol Cell Biochem"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40744-020-00258-9","article-title":"Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review","volume":"8","author":"\u00c1lvaro-Gracia","year":"2021","journal-title":"Rheumatol Ther"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/rheumatology\/key121","article-title":"Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1665293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:08:02Z","timestamp":1757311682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1665293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":43,"alternative-id":["10.3389\/fmed.2025.1665293"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1665293","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"article-number":"1665293"}}